Multiple sclerosis: Parkour athlete's loss of mobility 'mortifying'
Luke Callinan, 35, has been diagnosed with a rare form of multiple sclerosis. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 26, 2021 Category: Consumer Health News Source Type: news

Multiple sclerosis warning signs: What are the symptoms of MS? 10 early signs of MS
MULTIPLE SCLEROSIS is a devastating disease which can massively impact quality of life for sufferers, but what are the warning signs for this debilitating condition? (Source: Daily Express - Health)
Source: Daily Express - Health - July 25, 2021 Category: Consumer Health News Source Type: news

Biogen increases financial guidance despite 25% revenue drop
Biogen Inc. reported a 25% year-over-year revenue drop in its quarterly earnings Thursday, but investors remain bullish. In fact, the Cambridge biotech has upped its financial guidance by at least $200 million, to between $10.65 billion and $10.85 billion, for the 2021 fiscal year, bolstered by its growing multiple sclerosis portfolio and an expected increase of sales of the newly approved Alzheimer's disease drug Aduhelm. Total revenue attributable to Aduhelm in the second quarter of 2021 was $2… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 22, 2021 Category: Health Management Authors: Rowan Walrath Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

UCI-led study finds unleashing Treg cells may lead to treatments for multiple sclerosis
(University of California - Irvine) In a new University of California, Irvine-led study, researchers found that a certain protein prevented regulatory T cells (Tregs) from effectively doing their job in controlling the damaging effects of inflammation in a model of multiple sclerosis (MS), a devastating autoimmune disease of the nervous system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2021 Category: International Medicine & Public Health Source Type: news

Study may show why MS patients develop progressive disability
(Mayo Clinic) Did you know multiple sclerosis (MS) means multiple scars? New research shows that the brain and spinal cord scars in people with MS may offer clues to why they developprogressive disability but those with related diseases where the immune system attacks the central nervous system do not. In a study published in Neurology, Mayo Clinic researchers and colleagues assessed if inflammation leads to permanent scarring in these three diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2021 Category: International Medicine & Public Health Source Type: news

Study may improve understanding of how disability develops in MS patients versus those with related diseases
ROCHESTER, Minn. — Did you know multiple sclerosis (MS) means multiple scars? New research shows that the brain and spinal cord scars in people with MS may offer clues to why they developprogressive disability but those with related diseases where the immune system attacks the central nervous system do not. In a s tudy published in Neurology, Mayo Clinic researchers and colleagues assessed if inflammation leads to permanent scarring in these three diseases: MS.Aquaporin-4 antibody positive… (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - July 19, 2021 Category: Hospital Management Source Type: news

Quantitative MRI Towards Clinical Application in MS Quantitative MRI Towards Clinical Application in MS
Learn how quantitative MRI addresses the shortcomings of conventional MRI in terms of stratification of patients with multiple sclerosis, assessment of disease progression, and treatment response.Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 16, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Multiple Sclerosis Disease Burden Higher in Black Patients
WEDNESDAY, July 14, 2021 -- Black Americans with multiple sclerosis (MS) experience a higher disease burden than White patients, according to a study published online June 30 in Neurology. Karla Gray-Roncal, M.D., from the Johns Hopkins University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 14, 2021 Category: Pharmaceuticals Source Type: news

Biogen pays $125M for mid-stage, experimental multiple sclerosis drug
If approved, the drug would be Biogen's seventh for MS. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 13, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Biogen pays $125M for mid-stage, experimental multiple sclerosis drug
If approved, the drug would be Biogen's seventh for MS. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 13, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

High-Efficacy Therapy May Reduce Relapses in Active SPMS
TUESDAY, July 13, 2021 -- High-efficacy disease-modifying therapies may reduce flare-ups in recently active secondary progressive multiple sclerosis (SPMS), but they do not appear to offer any advantage over low-efficacy therapies for slowing... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 13, 2021 Category: Pharmaceuticals Source Type: news

Anti-tumor agent from the intestine
It is believed to be involved in the development of chronic inflammatory intestinal diseases, to trigger diabetes, to be responsible for obesity, even neurological diseases such as multiple sclerosis and Parkinson's could have their causes here - not to mention depressions and autistic disorders. We are talking about the microbiome - the vast collection of bacteria in the human gut. It is estimated that each person carries around 100 trillion bacterial cells in their digestive tract, belonging to several thousand species. (Source: World Pharma News)
Source: World Pharma News - July 9, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Why Do Black Patients Fare Worse When MS Strikes?
TUESDAY, July 6, 2021 -- While multiple sclerosis can cause a wide swath of symptoms and challenges for anyone diagnosed with the autoimmune disease, a new study finds that race may play a role in disease severity. Researchers discovered that Black... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 6, 2021 Category: General Medicine Source Type: news

Development of the better balance program for people with multiple sclerosis: a complex fall-prevention intervention - Comber L, Peterson E, O'Malley N, Galvin R, Finlayson M, Coote S.
BACKGROUND: Approximately 56% of people with multiple sclerosis (MS) will fall in any 3-month period, with the potential for physical, psychological, and social consequences. Fall-prevention research for people with MS is in its infancy, with a timely need... (Source: SafetyLit)
Source: SafetyLit - July 3, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

A Less Expensive, More Convenient Treatment Option for MS? A Less Expensive, More Convenient Treatment Option for MS?
Two phase 3 studies provide"delightful" new data for ublituximab, a novel investigational drug for multiple sclerosis, investigators report.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 30, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Dual-task speech performance in multiple sclerosis - Feenaughty L.
This study evaluated the presen... (Source: SafetyLit)
Source: SafetyLit - June 28, 2021 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

Roche ’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD)
Basel, 28 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved ENSPRYNG ® (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). ENSPRYNG is the first and only NMO SD treatment that is administered subcutaneously every four weeks, allowing home-dosing after appropriate training.“An NMOSD relapse can be devastating, causing permanent neurological damage ...
Source: Roche Media News - June 28, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD)
Basel, 28 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved ENSPRYNG ® (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). ENSPRYNG is the first and only NMO SD treatment that is administered subcutaneously every four weeks, allowing home-dosing after appropriate training.“An NMOSD relapse can be devastating, causing permanent neurological damage ...
Source: Roche Investor Update - June 28, 2021 Category: Pharmaceuticals Source Type: news

First Signs of MS May Often Go Undiagnosed
A new study suggests early symptoms of multiple sclerosis may commonly be missed for years before the right diagnosis is made. (Source: WebMD Health)
Source: WebMD Health - June 25, 2021 Category: Consumer Health News Source Type: news

First Signs of MS May Often Go Undiagnosed
MONDAY, June 28, 2021 -- Early symptoms of multiple sclerosis may commonly be missed for years before the right diagnosis is made, a new study suggests. Researchers found that patients with MS had a higher-than-average number of medical... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 25, 2021 Category: General Medicine Source Type: news

Certain ICD-10 Codes Often Precede Multiple Sclerosis Diagnosis
FRIDAY, June 25, 2021 -- Certain International Classification of Diseases (ICD), Tenth Revision (ICD-10) codes are recorded more frequently before the initial diagnosis in patients with multiple sclerosis (MS) compared with patients with other... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 25, 2021 Category: Pharmaceuticals Source Type: news

Zydus Cadila gets tentative USFDA nod to market generic sclerosis treatment drug
Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Fingolimod capsules, used in the treatment of multiple sclerosis, in the American market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 24, 2021 Category: Pharmaceuticals Source Type: news

In many cases, MS starts long before the diagnosis
(Technical University of Munich (TUM)) Years before they are diagnosed, persons with multiple sclerosis (MS) make significantly more visits to doctors and hospitals than others. Specialists have recently discussed whether this might represent a preliminary phase of MS - known as a prodrome. A research team at the Technical University of Munich (TUM) has now published results of a study suggesting that, in many cases, the complaints may relate to unrecognized early clinical MS events. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2021 Category: International Medicine & Public Health Source Type: news

' MIND' Diet Can Help Preserve Brain in People With MS
FRIDAY, June 18, 2021 – A diet designed to boost brain health appears to benefit people with multiple sclerosis (MS), new research suggests. For the study, a team from Icahn School of Medicine at Mount Sinai in New York City examined 185 people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 18, 2021 Category: General Medicine Source Type: news

Severity of Multiple Sclerosis Symptoms Tied to Race/Ethnicity
African American, Hispanic American race/ethnicity associated with greater disability, symptom severity in multiple sclerosis (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - June 16, 2021 Category: Psychiatry Tags: Family Medicine, Internal Medicine, Neurology, Pharmacy, Psychiatry, Anesthesiology & amp; Pain, Journal, Source Type: news

Severity of Multiple Sclerosis Symptoms Tied to Race/Ethnicity
WEDNESDAY, June 16, 2021 -- For patients with multiple sclerosis (MS), African American (AA) and Hispanic American (HA) race/ethnicity is associated with higher overall disability and higher symptom severity versus Whites, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 16, 2021 Category: Pharmaceuticals Source Type: news

CWRU researcher secures $1.2M to develop MS diagnostic tests
(Case Western Reserve University) Case Western Reserve University researcher Farren Briggs was awarded $1.2 million over three years from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health to identify biomarkers to improve the diagnoses of multiple sclerosis (MS), including the ability to monitor disease activity and progression. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2021 Category: International Medicine & Public Health Source Type: news

The effect of the Australian bushfires and the COVID-19 pandemic on health behaviours in people with multiple sclerosis - Marck CH, Hunter A, Heritage B, Gibbs L, Kermode AG, Walker DI, Learmonth YC.
BACKGROUND: Crises and disasters disproportionally impact people with chronic health conditions such as multiple sclerosis (MS). OBJECTIVE: To assess the impact of the COVID-19 pandemic and the Australian Black Summer Bushfires on health behaviours... (Source: SafetyLit)
Source: SafetyLit - June 8, 2021 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

What Are Some Indications for Using Dexamethasone?
Discussion Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Patients Taking Anti-Inflammatory Drugs Respond Less Well to COVID-19 Vaccine
(NYU Langone Health / NYU Grossman School of Medicine) One-quarter of people who take the drug methotrexate for common immune system disorders -- from rheumatoid arthritis to multiple sclerosis -- mount a weaker immune response to a COVID-19 vaccine, a new study shows. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 2, 2021 Category: Infectious Diseases Source Type: news

Out-of-pocket trends in Medicare Part D show rising costs for seniors
Anew study based on IQVIA data shows alarming trends in rising out-of-pocket costs for brand medicines among Medicare Part D beneficiaries with serious and complex conditions like cancer, HIV and multiple sclerosis. The analysis, which looked at spending trends among non-low-income subsidy (non-LIS) Part D beneficiaries from 2015 to 2019 across all brand medicines and several therapeutic areas, reaffirms the need for targeted solutions to strengthen the program. Here are three findings you should know.  (Source: The Catalyst)
Source: The Catalyst - May 24, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Part D Out-of-Pocket Costs Source Type: news

European Commission approves PONVORYTM (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features
BEERSE, BELGIUM, May 24, 2021 – Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced today that the European Commission (EC) has approved PONVORY (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.[4] “Relapsing multiple sclerosis is an unpredictable and complex disease that can present very differently from individual to individual, placing a heavy burden on the patient and their loved ones,” said Professor Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Professor of Neuro...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Novo Nordisk Prize for research on novel therapeutic approaches for brain diseases
(University of Freiburg) When Marco Prinz chose to study microglia after his medical studies, they were the most boring cells in the brain. Twenty-four years later, he is receiving the 2021 Novo Nordisk Prize for his pioneering studies of the crucial roles of these cells in the central nervous system, both in normal brain function and in connection with disease. His groundbreaking results form the basis for new diagnostic and treatment concepts for diseases such as multiple sclerosis and Alzheimer's. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 21, 2021 Category: International Medicine & Public Health Source Type: news

MS Linked to Lower Survival After Breast Cancer Diagnosis
Risk for all - cause mortality increased, but no association seen between multiple sclerosis and cancer - specific survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 20, 2021 Category: Cancer & Oncology Tags: Gynecology, Neurology, Oncology, Journal, Source Type: news

MS Linked to Lower Survival After Breast Cancer Diagnosis
THURSDAY, May 20, 2021 -- For women with breast cancer, those with multiple sclerosis (MS) have an increased risk for all-cause mortality compared with those without MS, according to a study published online May 19 in Neurology. Ruth Ann Marrie,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 20, 2021 Category: Pharmaceuticals Source Type: news

MS May Not Affect Breast Cancer Prognosis
WEDNESDAY, May 19, 2021 -- There's some reassuring news for women with multiple sclerosis (MS): Having the neurological disease won't affect health outcomes if breast cancer strikes. " Although multiple sclerosis and its complications remain the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 19, 2021 Category: General Medicine Source Type: news

Characterizing Chronic Pain Phenotypes in Multiple Sclerosis Characterizing Chronic Pain Phenotypes in Multiple Sclerosis
This study aimed to characterize and compare pain phenotypes in MS in terms of pain type and intensity, chronic overlapping pain conditions, and medication use and associated relief.Pain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Science Saturday: Explaining cholesterol, research and regeneration
Isobel Scarisbrick, Ph.D., directs the Neural Repair Laboratory within Mayo Clinic's Department of Physical Medicine and Rehabilitation. Her lab examines central nervous system repair after injury, such as traumatic spinal cord injury or a disease like multiple sclerosis (MS). A major area of innovation for the lab is improving nerve regeneration by identifying what helps or hinders that process. Cholesterol, the [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 15, 2021 Category: Databases & Libraries Source Type: news

Study finds low sugar metabolite associates with disability, neurodegeneration in MS
(University of California - Irvine) A new University of California, Irvine-led study finds low serum levels of the sugar N-acetylglucosamine (GlcNAc), is associated with progressive disability and neurodegeneration in multiple sclerosis (MS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2021 Category: International Medicine & Public Health Source Type: news

Low levels of a simple sugar -- A new biomarker for severe MS?
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) Researchers from the ECRC in Berlin, together with scientists from the United States and Canada, have discovered a sugar molecule whose levels are reduced in the blood of patients with particularly severe multiple sclerosis. Their discovery could pave the way for a new therapeutic approach, the team reports in medical journal JAMA Neurology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2021 Category: International Medicine & Public Health Source Type: news

The effect of yoga exercises on depression, overt and covert anxiety in women with multiple sclerosis - Shakhs Bolandghadr A, Noferesti A, Rostami R.
Multiple sclerosis is a disorder of the central nervous system that, in addition to physical symptoms, can lead to psychological symptoms such as depression and anxiety. In this regard, the present study aimed to determine the effectiveness of yoga trainin... (Source: SafetyLit)
Source: SafetyLit - May 10, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Mini 3D brain models could speed up search for MS treatments
(University of Edinburgh) Tiny 3-D models that mimic vital aspects of the human nervous system have been developed in a step that could accelerate drug research for neurological conditions such as multiple sclerosis (MS). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 3, 2021 Category: Biology Source Type: news

Social cognition plays a key role in everyday lives of people with multiple sclerosis
(Kessler Foundation) " We confirmed the longitudinal stability of social cognition deficits in cognitively-normal people with relapsing-remitting MS, mirroring the amygdala structural damage and psychological well-being, " said Dr. Genova. " These results confirm that social cognition exerts a key role in MS, affecting individuals' everyday lives. Our research highlights the need to identify treatments to improve social cognition in this population. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 3, 2021 Category: International Medicine & Public Health Source Type: news

Digital neurology startup MindMaze looks to the global market with slew of new deals
MindMaze creates gamified digital neurotherapeutics for patients with neurological injuries and conditions such as stroke, traumatic brain injury, multiple sclerosis or Parkinson ’s disease. (Source: mobihealthnews)
Source: mobihealthnews - May 3, 2021 Category: Information Technology Source Type: news

Younger Residents in Long-Term Care Find Meaning in Relationships, Engagement
Younger adults make up approximately 15% of the post-acute and long-term care patient population. They are more likely to be men and to have Medicaid as the primary payer (J Gerontol Nurs 2009;35:22-31). More younger adults in PALTC represent those with intellectual and developmental disabilities, individuals with neurological disorders such as multiple sclerosis and Huntington ’s disease, and those with serious mental illness. They are also more likely than their older counterparts to have experienced a traumatic injury that has resulted in profound loss of physical function due to hemiplegia or quadriplegia or loss...
Source: Caring for the Ages - April 28, 2021 Category: Health Management Authors: Elizabeth Galik Tags: Caring Collaborative Source Type: news

Highmark, Walgreens specialty pharmacy in social determinants of health pilot
Highmark has launched a pilot program with AllianceRx Walgreens Prime specialty pharmacy to reach out to its insurance members with multiple sclerosis to see what other types of services they may require. It's the latest of the Pittsburgh-based insurer's efforts around what are called the social determinants of health, the factors that aren't related to medical care but can make up to 80% of a person's health. Highmark and AllianceRx Walgreens prime will screen and then work with members, using… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 26, 2021 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Evobrutinib May Help Reduce MS Nerve Damage Evobrutinib May Help Reduce MS Nerve Damage
The highly selective Bruton's tyrosine kinase inhibitor may have a beneficial effect on lowering nerve damage in multiple sclerosis, new research suggests.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 23, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

CHMP recommends EU approval of Roche ’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ENSPRYNG® (satralizumab) as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spe ctrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). AQP4-IgG are present in around 70-80% of people with NMOSD, who tend to experience a more severe disease course.NMOS...
Source: Roche Media News - April 23, 2021 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ENSPRYNG® (satralizumab) as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spe ctrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). AQP4-IgG are present in around 70-80% of people with NMOSD, who tend to experience a more severe disease course.NMOS...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news